Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| U.S. Highbush Blueberry Council | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the impact of blueberries on uric acid in patients with hyperuricemia that are not receiving uric acid pharmacotherapy. The central hypothesis the investigators propose is that daily blueberries added to a pre-existing diet will promote uric acid lowering and improve quality of life without detriment to vital signs.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blueberry Powder | Active Comparator | Patients will take 30 grams of blueberry powder daily for up to 30 days. |
|
| Placebo Powder | Placebo Comparator | Patients will take 30 grams of placebo powder daily for up to 30 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blueberry Powder | Dietary Supplement | Patients will take 30 grams of blueberry powder daily for up to 30 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline and Placebo in Uric Acid Level in Patients Randomized to Treatment Group | Percent change in uric acid level from baseline after 30 days of treatment with blueberry powder. Since this is designed as a crossover trial, baseline could represent uric acid level at the beginning of the study or after at least a 2-week washout period following placebo administration. | Baseline, ~30 days later |
| Measure | Description | Time Frame |
|---|---|---|
| Blood Pressure | Percent change and absolute change of blood pressure from baseline and placebo | Baseline, ~30 days, ~45 days, ~75 days |
| Body Weight | Percent change and absolute change of body weight from baseline and placebo |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel Riche, Pharm.D. | University of Mississippi Medical Center | Principal Investigator |
| Marion Wofford, M.D., M.P.H. | University of Mississippi Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | United States |
Not provided
| ID | Term |
|---|---|
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Powder | Other | Patients will take 30 grams of placebo powder daily for up to 30 days. |
|
| Baseline, ~30 days, ~45 days, ~75 days |
| Quality of Life | Quality of life will be assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline, ~30 days, ~45 days, ~75 days |